Investors Have Until September 22 to Lead PROCEPT Lawsuit
News related to:PROCEPT BioRobotics Corporation · 2 min read
SAN FRANCISCO, Sept. 7, 2026 /CourierPR/ -- Investors in PROCEPT BioRobotics Corporation (PRCT) have until September 22, 2026, to lead a class action lawsuit against the company, according to a press release from the law firm Hagens Berman Sobol Shapiro LLP. The lawsuit alleges that PROCEPT violated federal securities laws by failing to disclose crucial information about its sales practices, particularly regarding its single-use handpieces.
The legal claims stem from a series of events that began in 2024. PROCEPT, which uses its proprietary Aquablation therapy to treat enlarged prostates, repeatedly touted growth in U.S. handpiece sales. However, the lawsuit contends that the company utilized an extensive discount program to incentivize bulk orders from customers, thereby pulling future sales into the present and inflating reported unit sales and revenues. This strategy, while seemingly boosting short-term performance, left customers with excess inventory and created long-term issues.
Investors began to learn the truth through a series of partial disclosures. On August 6, 2025, PROCEPT announced its Q2 2025 financial results, revealing that handpiece sales had unexpectedly deteriorated, missing consensus estimates by a wide margin. This was followed by the Q3 2025 results, which again missed expected handpiece unit sales. During the corresponding earnings call, management disclosed that the company was not managing customer inventory effectively, with some customers possibly carrying too much excess inventory.
The final blow came on February 25, 2026, with the announcement of Q4 2025 results. For the first time, PROCEPT disclosed the actual number of procedures in the field and revealed that U.S. handpiece sales had materially exceeded procedures since Q1 2023. Cumulative excess customer inventory of handpieces was over 10,000 units, and U.S. handpiece sales had sequentially cratered by 30%. In response, the company eliminated its previously undisclosed bulk order discount program, which had been designed to incentivize customers to make large purchases during the final weeks of every quarter.
The lawsuit alleges that these practices were not only improper but also led to a significant decline in the company's share price. By February 25, 2026, the price of PROCEPT shares had fallen by $22.06, or over 48% from the close on August 6, 2025. This decline was attributed to the growing awareness of the company's mismanagement of sales and inventory.
Hagens Berman Sobol Shapiro LLP is encouraging investors who purchased or otherwise acquired PROCEPT common stock between February 28, 2024, and February 25, 2026, to submit their losses. The firm is also seeking to identify individuals with non-public information that may assist in the investigation.
Reed Kathrein, the partner leading the firm's investigation, stated, "We are focused on whether PROCEPT may have intentionally pulled-in sales from future quarters to make it seem like the company was meeting expectations and, if so, whether the company had been sufficiently transparent in its investor communications."
If you invested in PROCEPT and have substantial losses, or if you have knowledge that could assist in the investigation, Hagens Berman Sobol Shapiro LLP encourages you to contact them now.